cbdMD annual stock-based compensation
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
cbdMD Stock-Based Compensation Growth & History (YCBD)
cbdMD's stock-based compensation was $14,121 for fiscal 2025.
View full cbdMD company overviewcbdMD annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-09-30 | $14,121 | −$2,779 | −16.44% |
| 2024 | 2024-09-30 | $16,900 | −$325,968 | −95.07% |
| 2023 | 2023-09-30 | $342,868 | −$585,957 | −63.09% |
| 2022 | 2022-09-30 | $928,825 | −$369,281 | −28.45% |
| 2021 | 2021-09-30 | $1.3M | −$602,088 | −31.69% |
| 2020 | 2020-09-30 | $1.9M | −$558,336 | −22.71% |
| 2019 | 2019-09-30 | $2.5M | $1.8M | +284.37% |
| 2018 | 2018-09-30 | $639,631 | $583,098 | +1031.43% |
| 2017 | 2017-09-30 | $56,533 | $45,083 | +393.74% |
| 2016 | 2016-09-30 | $11,450 | — | — |
cbdMD quarterly stock-based compensation
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
Q3.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q3 2026 | 2026-06-30 | $65,159 | $64,334 | +7798.06% |
| Q2 2026 | 2026-03-31 | $294,445 | $293,584 | +34098.03% |
| Q1 2026 | 2025-12-31 | $2,505 | — | — |
| Q4 2025 | 2025-09-30 | $10,428 | — | — |
| Q3 2025 | 2025-06-30 | $825 | — | — |
| Q2 2025 | 2025-03-31 | $861 | — | — |
| Q2 2022 | 2022-03-31 | $291,630 | $88,997 | +43.92% |
| Q1 2022 | 2021-12-31 | $505,466 | $256,572 | +103.08% |
| Q4 2021 | 2021-09-30 | $490,583 | −$18,340 | −3.60% |
| Q3 2021 | 2021-06-30 | $355,996 | −$63,050 | −15.05% |
| Q2 2021 | 2021-03-31 | $202,633 | −$227,018 | −52.84% |
| Q1 2021 | 2020-12-31 | $248,894 | −$293,680 | −54.13% |
| Q4 2020 | 2020-09-30 | $508,923 | $73,205 | +16.80% |
| Q3 2020 | 2020-06-30 | $419,046 | −$1.4M | −77.47% |
| Q2 2020 | 2020-03-31 | $429,651 | $410,176 | +2106.17% |
| Q1 2020 | 2019-12-31 | $542,574 | $398,901 | +277.65% |
| Q4 2019 | 2019-09-30 | $435,718 | $182,806 | +72.28% |
| Q3 2019 | 2019-06-30 | $1.9M | $1.5M | +422.89% |
| Q2 2019 | 2019-03-31 | $19,475 | $5,523 | +39.59% |
| Q1 2019 | 2018-12-31 | $143,673 | $126,559 | +739.51% |
| Q4 2018 | 2018-09-30 | $252,912 | $236,832 | +1472.84% |
| Q3 2018 | 2018-06-30 | $355,653 | $333,544 | +1508.63% |
| Q2 2018 | 2018-03-31 | $13,952 | $5,280 | +60.89% |
| Q1 2018 | 2017-12-31 | $17,114 | $7,442 | +76.94% |
| Q4 2017 | 2017-09-30 | $16,080 | — | — |
| Q3 2017 | 2017-06-30 | $22,109 | — | — |
| Q2 2017 | 2017-03-31 | $8,672 | — | — |
| Q1 2017 | 2016-12-31 | $9,672 | — | — |
cbdMD stock-based compensation trends
Over the last five fiscal years, cbdMD's stock-based compensation decreased from $1.9M to $14,121, a change of −$1.9M. The latest reported quarter, Q3 2026, shows $65,159.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review cbdMD source filings ↗